US › Healthcare

Unicycive Therapeutics Inc (UNCY)

US · Healthcare · Biotechnology

$5.17+2.27%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-12.8M

Profit YoY

-2349.6%

EPS

$-0.54

EPS estimate

$-0.47

EPS came in at -0.54 against a street estimate of -0.47 — a miss of 13.6%.

Key statistics

Market cap

$137.2M

Forward P/E

3.4

P/B

3.64

Book value

$1.49

EPS (TTM)

$-2.25

52-week high

$8.74

52-week low

$3.71

50-day MA

$6.42

200-day MA

$6.37

Beta

1.79

Analyst view

Analysts rate Unicycive Therapeutics Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $38.59.

Shareholding

Insiders

2.36%

Institutions

33.46%

Largest institutional holders

Fund	Stake
Vivo Capital, LLC	6.53%
Millennium Management LLC	5.11%
Octagon Capital Advisors LP	3.65%
Nantahala Capital Management, LLC	3.43%
Vanguard Capital Management, LLC	2.96%
Great Point Partners LLC	2.91%
Logos Global Management LP	1.73%
Citadel Advisors Llc	0.86%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Unicycive Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.